CN103687495A - Composition comprising vitamin k2 - Google Patents

Composition comprising vitamin k2 Download PDF

Info

Publication number
CN103687495A
CN103687495A CN201280035691.8A CN201280035691A CN103687495A CN 103687495 A CN103687495 A CN 103687495A CN 201280035691 A CN201280035691 A CN 201280035691A CN 103687495 A CN103687495 A CN 103687495A
Authority
CN
China
Prior art keywords
composition
blood
carboxylated
vitamin
farnoquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280035691.8A
Other languages
Chinese (zh)
Inventor
E·G·H·M·万登赫韦尔
R·M·L·茨维吉森
伊奥尼斯·玛尼欧斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FrieslandCampina Nederland BV
Original Assignee
Friesland Brands BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friesland Brands BV filed Critical Friesland Brands BV
Publication of CN103687495A publication Critical patent/CN103687495A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C13/00—Cream; Cream preparations; Making thereof
    • A23C13/12—Cream preparations
    • A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C17/00—Buttermilk; Buttermilk preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0921—Addition, to cheese or curd, of minerals, including organic salts thereof, trace elements, amino acids, peptides, protein hydrolysates, nucleic acids, yeast extracts or autolysate, vitamins or derivatives of these compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/001—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1578—Calcium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/161—Magnesium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/714—Vitamin K
    • A23V2250/7144—Vitamin K2

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to food products supplemented with micronutrients and, in particular, to a composition comprising vitamin K2. The composition further comprises calcium and magnesium, wherein the ratio Ca/Mg is less than 8. Optionally, the composition comprises polyunsaturated fatty acids and/or vitamin D. Preferably, the composition is a dairy composition and, more preferably, a yogurt. The composition according to the invention provides health benefits and can be used, in particular, for supporting, maintaining and/or improving of vascular elasticity and for the prevention of vascular hardening. It is further effective for supporting, maintaining and/or improving blood circulation and/or blood flow of micro- and/or macrovascular system; and/or for improving blood transfusion and the transfusion of oxygen and nutrients to the tissues and for the removal of waste and carbon dioxide from the tissues; and/or for keeping an adequate energy level.

Description

The composition that comprises farnoquinone
Technical field
The present invention relates to field of nutrition, and be specifically related to comprise and/or be supplemented with the product of micronutrient.Particularly, the food that the present invention relates to comprise vitamin, mineral matter or other micronutrient and these products are for promoting the application of mammiferous cardiovascular health, and these products are specifically for supporting and/or improve the application of blood vessel elastic force.
Background technology
Due to come into one's own gradually healthy consumer's popular welcome of functional food, functional food becomes field emerging in food science.Functional food is any food or the COF that the health benefits that surmounts wherein included traditional nutrient can be provided.The general classes of functional food comprises finished food or through the food of sanatory reinforced by additive, for example, and the product that vitamin is abundant.
The advantage that functional food surpasses the conventional food replenishers that contain a kind of active component or various active composition is: active component is not merged in conventional food product to for example do not need and gives separately with the form of replenishing vitamins tablet.
Although much the food through dietary supplement ingredient strengthening is known, for example, to providing the demand of the functional food of concrete health benefits (cardiovascular health) constantly to increase.
Yet the traditional food that is supplemented with vitamin and/or mineral matter does not always show the desired health benefits of micronutrient based on added.The micronutrient adding should be compatible with each other and with food in contained other composition compatible.In addition, the interpolation of vitamin also may have adverse effect to the perception of supplementary (sensoric) characteristic, such as taste, smell or denseness.In addition often expect, good preservation (keeping) property and the heat endurance of products obtained therefrom.
Summary of the invention
In order to solve better aforementioned one or more requirement, the present invention provides a kind of composition that comprises farnoquinone, calcium and magnesium in aspect first, and wherein, the part by weight of calcium/magnesium is less than 8.
Surprisingly, find: can be effectively for preventing vascular sclerosis and/or improvement, support and/or maintain elasticity and/or the intensity of blood vessel according to composition of the present invention.Can improve by this way, support and/or maintain healthy blood circulation and/or CBF (blood flow).
The present invention relates to be generally used for the food composition of current consumption type, and special purport produces the food composition of positive role type in the health to the mankind or animal, and/or purport is in the food composition that improves, supports and/or maintain inconvenience (inconvenience) type of the mankind or animal.
According to the neccessary composition of composition of the present invention, be farnoquinone or methylnaphthoquinone.Farnoquinone is the member of vitamin K group, and vitamin K group is one group of liposoluble vitamin.The total methylated naphthoquinones ring structure of all members of vitamin K group, and different in the connected aliphatic lateral chain of 3-position.Phylloquinone (being also referred to as phytomenadione) always contains 4 isoprenoid residues on its side chain, and a residue in these 4 isoprenoid residues is undersaturated.Menaquinone has the side chain that the unsaturated isoprenoid residue by variable number forms, and they are designated as MK-n conventionally, wherein the quantity of n specified class isoprene.
The group of vitamin K relates to blood clotting and calcium metabolism.Vitamin K is absolutely necessary to the carboxylation of the glutaminic acid residue in some protein.The protein requirement carboxylation that these vitamin Ks rely on has biologically active to become.Although clotting factor (coagulant factor) is the protein that the most well-known vitamin K relies on, the protein that also has a lot of other vitamin Ks to rely on has important physiological action.Matrix Gla protein (MGP), BGP and growth inhibition specific gene 6(Gas-6) be the protein of the vitamin K dependence of three kinds of particular importances.Vitamin K is common in B B-complex replenishers and babies ' formula milk powder.Yet vitamin K mainly exists with the form of phytomenadione.Therefore, in fact the vitamin K of general appointment refers to phytomenadione, because it is quite cheap to obtain the vitamin K of this form, and since a very long time, has generally believed that it is safety in food.
Can for example,, from any applicable source (, from the fermented soybean prod such as natto), obtain the farnoquinone in the present invention.The farnoquinone of synthetic preparation is also applicable to, because it has advantage: the quality that can control at an easy rate the farnoquinone of such acquisition.Yet, preferably from natural origin, (for example, pass through micro-organisms) and obtain farnoquinone.
In description, the farnoquinone in composition according to the present invention and the content of other composition characterize with the amount taken in every day or with the amount of every portion of food (serving).For the product of viscosity (can dip), serving (serving) is about 125g; Or for dumpable products such as milk or boruga, serving is about 200～250ml.For cheese, serving refers to approximately a slice of 30～40g; And for the sauce (spread) or the butter that conventionally use together with a slice of bread, serving is about 3.5～7g.Take in every day and refer to the total amount with the composition that consume every day in one or more products of the present invention.Every day, absorption may be consumed in serving, but also can be divided into 2 parts, 3 parts, 4 parts of every day or more portions of foods even.Every day, absorption also can be distributed on several prods, such as milk and Yoghourt, milk and cheese etc.Information based on provided, technical staff can find the applicable amount of many parts, or the applicable combination of product.For example, the Yoghourt that general every daily consumption can dip and drink once or twice, therefore, is taken in normally every day serving or two portions of foods every day.For cheese, every day, absorption was commonly referred to as a slice every day, but can be also more.For sauce or butter, suppose 4 bread of average every daily consumption, every day, absorption was commonly referred to as approximately 4 parts.Yet, lower or higher amount part be also possible, kind and content that this depends on product, also depend on consumer's custom.
According to composition of the present invention, preferably comprise and take at least farnoquinone of 5mcg every day.Because farnoquinone promotes blood clotting (this blood clotting may be undesirable), so being preferably, the upper limit that take in the every day of farnoquinone in composition is less than 200mcg.More preferably, composition contains takes in 5～150mcg every day, and the farnoquinone of 7～100mcg even more preferably.More preferably, composition contains the farnoquinone of taking in 10～90mcg every day.More preferably, every day, the amount of farnoquinone was 15～75mcg, 25～60mcg even more preferably, and every feed ration of even more preferably 35～50mcg, and farnoquinone most preferably is 40～45mcg.For object of the present invention, the meaning of " mcg " is microgram.In a preferred embodiment, farnoquinone contains 4～13 isoprenoid residues, especially contains 6～13 isoprenoid residues.More preferably, farnoquinone contains 6～10 isoprenoid residues, is specially 6,7,8,9 or 10 residues.These forms of farnoquinone (especially MK-6 and Geng Gao), compare and have relatively high biological effectiveness with the menaquinone with less isoprenoid residue.
According to composition of the present invention, further contain mineral calcium and magnesium.Be understandable that, can use calcium and the magnesium in any type of food-grade source.These comprise organic and inorganic compound, salt, molecular complex, chelating agent, such as calcium citrate, calcium carbonate, calcium gluconae, calcium lactate, calcium phosphate, magnesia, magnesium citrate etc.For magnesium, preferred source is magnesium citrate.As for calcium, the example in the applicable source of calcium is the part (milk part) of dairy products product or dairy component, particularly milk and milk.
In the preferred embodiment of the present invention and embodiment thereof, calcium (Ca) preferably be take absorption every day as 20～1600mg, is preferably 70～1000mg, and more preferably 80～800mg amount is present in composition of the present invention.In this composition, the amount of calcium is preferably and takes in 100～600mg every day, more preferably takes in 150～500mg every day, more preferably takes in 200～450mg every day, even more preferably take in 250～400mg every day, and most preferably be the calcium of taking in 300～350mg every day.For object of the present invention, " mg " plan refers to mg.
In the preferred embodiment of the present invention and embodiment thereof, the content of magnesium (Mg) is preferably and takes in 20～800mg every day, 30～600mg more preferably, and 50～500mg even more preferably, more preferably take in 75～400mg every day, 100～300mg even more preferably, even more preferably 150～250mg and most preferably be the magnesium of 160～200mg.In the preferred embodiment of the present invention and embodiment thereof, it is magnesium that composition comprises the calcium and the 50～300mg that take in 80～800mg every day, or the calcium of 100～600mg and the magnesium of 75～400mg, or the calcium of 150～500mg and the magnesium of 100～300mg.If composition according to the present invention is dairy composition, one preferred embodiment in, dairy component is unique source of calcium, that is to say, composition does not have the calcium outside supplementary quota.Therefore, in this embodiment, the level of calcium, corresponding to the level of the calcium in milk, that is to say, the calcium of every 100g50～200mg, or the calcium of every part of food 60～400mg.In this case, the calcium of taking in every day is preferably 80～800mg, 100～700mg more preferably, and 120～600mg even more preferably, and be particularly preferably 240～500mg and 300～450mg even more preferably, and most preferably be the calcium of 350～400mg.But in the preferred embodiment of the present invention and embodiment thereof, dairy composition can be supplemented with extra calcium, the total amount that makes calcium is to take in every day, for example, 100～1200mg, and be preferably 120～1000mg and 240～800mg even more preferably, 300～700mg more preferably, even more preferably 400～600mg and most preferably 450～550mg.
Indispensable for the present invention: the part by weight of calcium/magnesium (Ca/Mg) is less than the part by weight in milk.In normal milk, naturally calcium/magnesium ratio is approximately 10.Preferably, Ca/Mg ratio is not more than 8, and more preferably no more than 6, such as 5 or still less.More preferably, Ca/Mg ratio is not more than 3.5, and even more preferably no more than 3.The preferable range of calcium/magnesium ratio is 0.5～2.7.Ca/Mg ratio is particularly preferably in 1.5～2.4 scope, and for example, Ca/Mg ratio is approximately 1.7～2.2 or 1.8～2.Low calcium/magnesium ratio relates to each product or every portion of food individually.If the every day of farnoquinone, absorption can be dispersed in several portions of foods or several product, so must be in described scope for every portion of food or each products C a/Mg ratio.
As shown in embodiment, in order to reach same health effect, best Ca/Mg ratio is allowed the farnoquinone of required small amount.By this way, every portion of food or every day take in and to need less farnoquinone.This risk with the blood coagulation that generation is associated with the farnoquinone of high dose is less; This also allows and reduces costs, because farnoquinone ratio is as more expensive in phytomenadione.
In the preferred embodiment of the present invention and embodiment thereof, according to the calcium/phosphorus ratio of composition of the present invention, be 0.5～5, more preferably 1～4, more preferably 1.5～3.5, and most preferably be 2～2.5.For dairy products product (such as Yoghourt), this ratio is preferably 1～2.
In the preferred embodiment of the present invention and embodiment thereof, said composition further comprises at least one polyunsaturated fatty acid (PUFA).PUFA is the aliphatic acid that contains more than one pair of key on main chain.This class comprises many important compounds, such as essential aliphatic acid, for example, ω-3 and ω-6 aliphatic acid.
In the present invention, particularly long-chain polyunsaturated fatty acid (LC-PUFA) is applicable to, and preferably those have the long-chain polyunsaturated fatty acid of at least 20 carbon atoms in molecule.This long-chain omega-fatty acid comprises: cis-11, 14, 17-eicosatrienoic acid (ETE) C20:3, cis-8, 11, 14, 17-eicosatetraenoic acid (ETA) C20:4, cis-5, 8, 11, 14, 17-eicosapentaenoic acid (EPA) C20:5, cis-7, 10, 13, 16, 19-clupanodonic acid (DPA, clupanodonic acid) C22:5, cis-4, 7, 10, 13, 16, 19-DHA (DHA) C22:6, cis-9, 12, 15, 18, 21-tetracosa carbon pentaene acid C24:5, cis-6, 9, 12, 15, 18, 21-nisioic acid (nisinic acid) C24:6.Long-chain omega-6 aliphatic acid with at least 20 carbon atoms comprises: cis-11, 14-bis-dodecadienoic acid C20:2, cis-8, 11, 14-eicosatrienoic acid (dihomo-gamma-linolenic acid) is C20:3 (DGLA), cis-5, 8, 11, 14-eicosatetraenoic acid (arachidonic acid) C20:4 (AA), cis-13, 16-bis-dodecadienoic acid C22:2, cis-7, 10, 13, 16-docosatetraenoic acid (adrenic acid (adrenic acid)) C22:4, cis-4, 7, 10, 13, 16-clupanodonic acid (this Bond's acid (Osbond acid) difficult to understand) C22:5.LC-PUFA preferably be take absorption every day and is existed according in product of the present invention as 20～1000mg and the amount that is preferably 30～500mg.
Particularly preferred LC-PUFA is EPA C20:5, DHA C22:6 and their combination.In all sources of PUFA, animal origin is preferably to use, specifically fish oil and marine oil, or algal oil.In embodiments of the present invention, the fish oil obtaining from cod liver, catfish (herring), mackerel, salmon, oily catfish (menhaden) and sardine is used as the source of LC-PUFA.According to composition of the present invention, preferably with the amount of taking in 10～500mg every day and being preferably 30～350mg, contain EPA, DHA or their combination.Particularly preferably being absorption every day is the EPA of amount and the combination of DHA of 40～250mg.
According to the present invention and the composition of embodiment can further contain other vitamin and/or mineral matter, emulsifying agent, colouring agent, anticorrisive agent, natural gum, thickener.If PUFA is for composition, preferably use antioxidant, such as vitamin C, vitamin E, selenium, polyphenol, bioflavonoid, to prevent the oxidation of LCFA, the oxidation of LCFA can make product produce unwanted taste variation and short shelf-life.
In the preferred embodiment of the present invention and embodiment thereof, said composition further contains vitamin D, and is preferably neo dohyfral D3.The amount of vitamin D can be for taking in 0.25～6mcg every day, and be preferably 1～5mcg, more preferably 2～4mcg and most preferably 2.5～3.5mcg.As used herein, " vitamin D " refers to the vitamin D of any form known, and specifically comprise: precursor, metabolite and other analog of calciferol (ergocalciferol), neo dohyfral D3 (cholecalciferol), vitamin D, with their combination, and various activity contains the vitamin D with inactive form.For example, can using that it provides neo dohyfral D3 without hydroxylated inactive form as cholecalciferol, or also can using that it provides neo dohyfral D3 through hydroxylated activity form as calcitriol.
In another preferred embodiment of the present invention and embodiment thereof, said composition contains cobalamin (various cobalamin).This vitamin contributes to energetic supersession, erythrocyte formation, immune function and mental health.Because the absorption by enteron aisle is along with the age declines, the mankind and particularly in the elderly, the blood level of suboptimum is quite common.The blood level of low cobalamin causes macrocytic anemia disease, increases homocysteine rising, peripheral neuropathy, memory loss and other cognitive defect of suffering from risk of cardiovascular diseases.The preferred amount of cobalamin is that to take in every day be 0.25～3mcg, and is preferably 0.375～2mcg, 0.45～1.75mcg more preferably, and 0.5～1.5mcg more preferably, 0.75～1.3mcg even more preferably, and most preferably be 0.9～1.2mcg.
In a preferred embodiment, according to the present invention and the composition of embodiment be dairy composition, dairy composition is understood to further contain at least one the composition in following composition: the composition of butter oil, lactoprotein, defatted milk or other milk.The product that term dairy composition also comprises milk and obtains based on milk or the processing by milk, such as cream, cheese, milk powder, tartar sauce, Yoghourt, other fermented-milk products.
In dairy composition, low Ca/Mg ratio described in the present invention has further actively impact to the taste of product, particularly Yoghourt (such as fruit yoghurt drinks) is had further to actively impact.For example, due to the peculiar smell being caused by nutritious supplementary pharmaceutical (off-flavour), and especially by add the peculiar smell that the aliphatic acid of (even low amount) causes, the taste of Yoghourt may become and be not suitable for.Therefore the PUFA(, adding is such as fish oil) taste should often be sequestered in the dairy composition with extra taste reagent (taste agent).Astoundingly, low Ca/Mg ratio (such as lower than 8 and preferably lower than 5) provides better taste and can shelter the PUFA taste in Yoghourt, and does not need to add taste improving agent.This effect is advantageous particularly in fruit yoghurt drinks composition.
Preferably, composition according to the present invention is food or beverage products, or dietary supplements.Most preferably, composition according to the present invention is dairy products food.
In one embodiment, according to the present invention and the composition of embodiment be Yoghourt or other fermented-milk products, such as cheese, butter milk, French whipping cream, the sour cream of cheese, processing.Yoghourt can have dense denseness (Yoghourt that can dip), or has dumpable denseness (drinking Yoghourt).In a preferred embodiment, product is fruit yoghurt drinks or the dairy products that contains fruit syrup.
In another embodiment, this product is the milk based on non-fermentation, for example, and milk beverage, milk shake, fruit-milk beverage, chocolate milk.In another other embodiment of the present invention, this product is cream, whipping (whippable) cream, dairy products class sauce, ice cream, butter, margarine, melange (melange), béchamel sauce, cures cream (bakery cream) etc.
Can prepare according to product of the present invention in any mode easily well known by persons skilled in the art.In a preferred embodiment, by being applicable to the farnoquinone in source, the magnesium in applicable source, and optionally the calcium in applicable source is added in food, prepares according to composition of the present invention.Be appreciated that applicable source is to contain required vitamin or the source of key element (such as compound or composition), this source is suitable in food (food-grade).Preferably, bioavailable form (such as chelated forms or as acylate) contained in applicable source vitamin or mineral matter.The mineral matter of animal origin is better than the mineral matter of plant origin.Can carry out blending constituent with any traditional approach well known by persons skilled in the art.For example, can first farnoquinone be dissolved in fat mutually in, simultaneously calcium and/or magnesium, in water, then carry out emulsification and are added in food to be strengthened.Also can use farnoquinone with powder type, and be added in the residual components in water or be added directly in product.
When preparing dairy products product, preferably only farnoquinone and magnesium are added in product in one embodiment, and do not add extra calcium.Then, due to the initial existence of calcium in dairy products product, and obtain desired Ca/Mg ratio by adding magnesium.Yet, in another embodiment, for example, when product contains fruit syrup, add the calcium of some additional quantity to reach required level.
According to product of the present invention, can be advantageously used in and maintain, support and/or promote mammiferous cardiovascular health, and the mankind's cardiovascular health specifically.Particularly, described composition can be for maintaining, support and/or promoting blood vessel elastic force, and/or for preventing vascular sclerosis.And, described composition can: effectively for maintaining, support and/or improve blood circulation and/or the blood flow of Microvasculature and/or trunk (macrovascular) system; And/or for maintaining, support and/or improving the transportation of the oxygen of tissue and nutriment and/or refuse and the removal of carbon dioxide from organizing; And/or maintain, support and/or promote sufficient energy level, specifically for the tissue (comprising: heart, brain, skeletal muscle, liver and kidney) of oxygen high flow rate; And/or keep fit and mental health.
Another aspect of the present invention relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve vascular health, especially cardiovascular health.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve vascular elasticity.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or maintain and/or reduce arterial stiffness (arterial stiffness).
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve bone health.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve normal blood coagulation ability, and/or maintain normal platelet aggregation, and/or prevent that blood platelet is attached on vascular wall and/or fatty patch.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve glucose control and/or insulin secretion and/or insulin sensitivity.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or maintain and/or reduce chronic inflammation and/or low grade inflammation.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve mental health and/or cognitive performance and/or alertness, and/or psychological definition (mental sharpness) and/or memory.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve healthy body weight, and/or healthy body mass index (BMI), and/or healthy triglycerides blood level, and/or healthy waistline.The health status of all health parameters of mentioning is in the present invention preferably according to World Health Organization's criterion (the WHO criterion of the prevention of diabetes, management and nursing, 2006; Diet, body movement and healthy global strategy, the WHO report of 2004)
The invention further relates to according to the present invention or the composition of its embodiment maintains healthy blood pressure and/or prevention and/or reduces hypertension (according to WHO criterion).
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve blood flow.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve blood circulation, comprise systemic circulation and/or microcirculation.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve hemoperfusion.This is that blood is transported to capillary bed to the process of mammiferous tissue, such as being transported to brain, kidney, heart, lung, liver, four limbs and being transported to stomach intestinal tissue.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or the metabolic syndrome that maintains and/or reduce.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of vascular diseases, and/or angiocardiopathy, and/or atherosclerotic, and/or artery sclerosis, and/or arterial stiffness and/or hypertension and/or obstruction of artery and/or varication and/or transient ischemic attack (TIA) and/or apoplexy and/or peripheral coldness (cold limb).
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of blood vessel and lacks flexibility.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of bone demineralization and/or osteoporosis.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of DVT and/or apoplexy.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of diabetes and/or insulin resistance.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of chronic inflammation and/or low grade inflammation.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of psychology go down (mental decline) and/or mental disease, such as dementia and/or Alzheimer's.
The invention further relates to according to the present invention or the composition of its embodiment is used for the treatment of obesity, and/or metabolic syndrome, and/or high BMI, and/or the high triglyceride in blood, and/or high body weight, and/or high waistline.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve vascular health, and/or the application of cardiovascular health.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the application of blood vessel elasticity.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or maintain and/or reduce the application of arterial stiffness.
The invention further relates to according to the present invention or the composition of its embodiment maintains healthy blood pressure and/or prevention and/or reduces the application of hypertension (according to WHO criterion).
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the application of blood flow.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the blood circulation application of (comprising systemic circulation and/or microcirculation).
The invention further relates to according to the present invention or the composition support of its embodiment, maintain and/or improve the application of hemoperfusion.This is that blood is transported to capillary bed to the process of mammiferous tissue, such as being transported to brain, kidney, heart, lung, liver, four limbs and being transported to stomach intestinal tissue.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the application of bone health.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve normal blood coagulation ability and/or maintain normal platelet aggregation and/or prevention blood platelet is attached to the application on vascular wall and/or fatty patch.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve glucose controlling mechanism, and/or insulin secretion and/or insulin sensitivity, and/or the application of prevention diabetes and/or hyperglycemia.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or maintain and/or reduce the application of chronic inflammation and/or low grade inflammation.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the application of mental health and/or cognitive performance and/or alertness and/or memory and/or psychological definition.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain and/or improve the application of the increase of healthy weight management and/or healthy body mass index and/or healthy triglycerides blood level and/or prevention body fat amount.
The invention further relates to according to the present invention or the composition support of its embodiment and/or maintain healthy waistline and/or reduce the application of high waistline.
The invention further relates to according to the present invention or the composition prevention of its embodiment and/or maintain and/or reduce the application of metabolic syndrome.
The invention further relates to according to the present invention or the composition of its embodiment strengthens the application of the biological effectiveness of vitamin K and/or farnoquinone.
The invention further relates to according to the present invention or the composition raising vitamin K of its embodiment and/or the bioactive application of farnoquinone.
The invention further relates to according to the present invention or application that the composition of its embodiment improves the level of vitamin K in mammalian and/or farnoquinone.
The invention further relates to according to the present invention or the MGP that is reduced in the not carboxylated circulating in mammalian and/or the not application of the level of the BGP of carboxylated of the composition of its embodiment.
The invention further relates to according to the present invention or application that the composition of its embodiment improves the level of the MGP of carboxylated that circulates in mammalian and/or the BGP of carboxylated.
In the preferred embodiment of the present invention and embodiment thereof, in 12 weeks, preferably in 8 weeks, more preferably in 4 weeks, obtain MGP and/or the not reduction of the level of the BGP of carboxylated of the not carboxylated of circulation, and/or in blood, circulate the MGP of carboxylated and/or the increase of the BGP cyclical level of carboxylated, and/or the increase of the level of the vitamin K in mammalian and/or farnoquinone.
The invention further relates to a kind of MGP of the not carboxylated circulating in mammalian and/or method of the level of the BGP of carboxylated not of being reduced in, by mammal being given according to the present invention or the composition of its embodiment.
The invention further relates to a kind of method that is increased in the level of the MGP of the carboxylated circulating in mammalian and/or the BGP of carboxylated, by mammal being given according to the present invention or the composition of its embodiment.
The invention further relates to the method for the level of the farnoquinone of a kind of raising in mammalian, by mammal being given according to the present invention or the composition of its embodiment.
Preferably, according to the present invention or in the method for its embodiment, giving according to the present invention or at least 4 weeks of composition of its embodiment preferably at least 8 weeks and the most preferably time period at least 12 weeks.Preferably, give according to the present invention throughout one's life or the composition of its embodiment, give aptly 3,5,7,10,12,15,18,20,23,25,27,30,32,35,38,40,45,50,55,60,65,70,75,80,85,90 or even up to 95 years.Preferably take in vitamin K and/or farnoquinone and/or MK-7 every day (every day), to maintain the vitamin K in blood, the maintenance level of farnoquinone.Can easily product of the present invention be incorporated in normal health diet, make every day, improve throughout one's life the level of vitamin K and farnoquinone.
The specific embodiment
To further set forth the present invention with nonrestrictive embodiment below.
embodiment 1
In order to study the dairy products product that has high-caliber phytomenadione, farnoquinone or the there is no vitamin K effect after treatment in a year, 3 kinds of different treatments using parallel design in 1 year get involved (intervention) to postmenopausal women (45-65 year).Three treatment groups (treatment arm) are:
Control group: take in the every day that 2 portions of dairy products (selection of milk or Yoghourt) contain 10mcg vitamin D and 800mg calcium.The Ca/Mg ratio of taking in every day is at about 10(milk only) to about 15(Yoghourt only) between change.
Phytomenadione group: take in the every day that 2 portions of dairy products (selection of milk or Yoghourt) contain 100mcg phytomenadione, 10mcg vitamin D and 800mg calcium.The Ca/Mg ratio of taking in every day is at about 10(milk only) to about 15(Yoghourt only) between change.
Farnoquinone group: take in the every day that 2 portions of dairy products (selection of milk or Yoghourt) contain 100mcg farnoquinone, 10mcg vitamin D and 800mg calcium.The Ca/Mg ratio of taking in every day is at about 10(milk only) to about 15(Yoghourt only) between change.
Before 1 year intervention phase and afterwards, extract blood sample.In these blood samples, analyze the carboxylated degree (grade) of MGP to obtain the not ucMGP of carboxylated and the ratio of MCP (ucMGP/MGP ratio), MGP is the cMGP of carboxylated and the summation of the ucMGP of carboxylated not.In the state of the art, this is considered to vascular health, the mark of correlation thing of angiosteosis specifically.The calcification that suppresses blood vessel in order to keep blood vessel elasticity is considered to be by the active adjustment process of bioactive (carboxylated) MGP.Result provides in table 1.
Table 1: according to the variation of the ucMGP for the treatment of group and ucMGP/MGP percentage.
Figure BDA0000458559030000131
Figure BDA0000458559030000141
*: compared significant difference with control group with phytomenadione group.
Figure BDA0000458559030000142
compared significant difference with control group.
After treatment in a year, the absorption in dairy products product with the dairy products product of high-caliber farnoquinone makes %ucMGP/MGP reduce by 17%.So the abundant product of vitamin K has beneficial effect to blood vessel elastic force.Surprisingly, the abundant dairy products product of phytomenadione only has little and inapparent effect to vascular health parameter.This effect can be compared with the control group with the dairy products product that is added with vitamin D and calcium.In a word, farnoquinone is more effective for blood vessel elastic force, and phytomenadione is invalid.The application that is added with the dairy products product of vitamin D and calcium has little and inapparent effect to the health parameters of blood vessel.
embodiment 2
Be added with the dairy products product effect of 3 months of farnoquinone and the Ca/Mg of medium level
To postmenopausal women and man's (45-65 year) carried out 3 months with parallel design.In this research, the dairy products product of mixture with farnoquinone, fish oil and the low Ca/Mg ratio of medium level is contrasted with the dairy products product that does not add nutrient.
Two treatment groups are:
Control group: every day 2 parts of each 250ml Yoghourt, these do not contain DHA or EPA, contain 0mcg vitamin D and have approximately 10 Ca/Mg ratio.
Treatment group: every day 2 parts of each 250ml Yoghourt, and fish oil; Wherein, take in the every day that Yoghourt contains 56.5mcg farnoquinone, 3.75mcg neo dohyfral D3,600mg calcium, 280mg magnesium, and fish oil contains 200mg DHA and EPA.Ca/Mg ratio is 2.1.
Get involved 1,2 and 3 months before and afterwards, taked blood sample.In these blood samples, analyzed the carboxylated degree of MGP to obtain the not ucMGP of carboxylated and the ratio of MGP (ucMGP/MGP ratio), MGP is the cMGP of carboxylated and the summation of the ucMGP of carboxylated not.Result is shown in table 2.
Table 2: according to the variation of the cMGP for the treatment of group and treatment time, ucMGP and ucMGP/MGP percentage (ucMGP/MGP% ratio)
* compared significant difference with baseline, P<0.01
After treatment, the absorption that is added with the dairy products product of nutrient farnoquinone (56.5mcg every day) has significantly reduced ucMGP/MGP.This effect occurs in each testing time section and in time to be increased.Corresponding 1,2 and 3 months after, ucMGP/MGP has reduced respectively 8,14 and 17%.Surprisingly, unique mixture (farnoquinone and the low Ca/Mg ratio with medium level) with take for a long time the product (as shown in Example 1) same effectively (i.e. 17% improvement) with homovitamin K2 level.In addition, as in long-term Interposed test, dairy products have little and inapparent effect.
Due to safety/antithrombotic reason, LC-PUFA(is EPA and DHA specifically) be included in composition to reverse the thrombotic effect of vitamin K.It is believed that, LC-PUFA does not have help to blood vessel elastic force label MGP.Therefore, viewed effect is the combination due to low Ca/Mg ratio and farnoquinone.
Therefore the conclusion, drawing: best Ca/Mg ratio and the combination of farnoquinone play a role quickly product under the farnoquinone of reduced levels.This experiment has shown that this constituents mixt is synergistic.

Claims (30)

1. a composition that comprises farnoquinone, calcium and magnesium, wherein, the part by weight of calcium/magnesium is less than 8.
2. composition according to claim 1, wherein, the ratio of Ca/Mg is less than 3.5, and preferably in 1.5～2.4 scope.
3. composition according to claim 1 and 2, wherein, farnoquinone exists to take in the amount of 5mcg～200mcg every day.
4. according to the composition described in any one in aforementioned claim, wherein, farnoquinone contains 6～13 isoprenoid residues.
5. according to the composition described in any one in aforementioned claim, wherein, calcium exists to take in the amount of 20mg～1600mg every day.
6. according to the composition described in any one in aforementioned claim, wherein, magnesium exists to take in the amount of 20mg～800mg every day.
7. according to the composition described in any one in aforementioned claim, described composition further comprises at least one long-chain polyunsaturated fatty acid with at least 20 carbon atoms (LC-PUFA).
8. composition according to claim 7, wherein, described LC-PUFA is eicosapentaenoic acid (EPA), DHA (DHA) or their mixture.
9. composition according to claim 8, wherein, described EPA, DHA or their mixture be take the amount that absorption every day is 10mg～500mg and are existed.
10. according to the composition described in any one in claim 7～9, wherein, described LC-PUFA exists with the form of fish oil.
11. according to the composition described in any one in aforementioned claim, and described composition further comprises the vitamin D of the amount of taking in 0.25mcg～6mcg every day.
12. according to the composition described in any one in aforementioned claim, and described composition further comprises the cobalamin of the amount of taking in 0.25mcg～3mcg every day.
13. 1 kinds of dairy products food, described dairy products food product packets is containing according to the composition described in any one in aforementioned claim.
14. dairy products food according to claim 13, described dairy products food is cheese, butter milk, French whipping cream, sour cream, dairy products class sauce, margarine, melange, milk or the dairy cream of the Yoghourt that can dip, boruga, cheese, processing.
15. dairy products food according to claim 14, described dairy products food is fruit yoghurt drinks or the milk that contains fruit syrup.
16. 1 kinds for the preparation of according to the method for the dairy products food described in any one in claim 13～15, described method comprise by farnoquinone, magnesium and optionally calcium be added in food.
17. 1 kinds according to the composition described in any one in claim 1～12, described composition in order to support healthy and mental health for supporting, maintaining and/or improve blood vessel elastic force, and/or for preventing vascular sclerosis; And/or for supporting, maintain and/or improve blood circulation and/or the blood flow of Microvasculature and/or trunk system; And/or for supporting, maintain and/or improving the blood transport of tissue and/or the conveying of oxygen and nutrient, and/or the removal from organizing for refuse and carbon dioxide; And/or for keeping sufficient energy level.
18. 1 kinds according to the composition described in any one in claim 1～12, described composition support and/or maintain and/or improve to be selected from and comprise vascular health, cardiovascular health, blood flow, blood circulation, the systemic circulation of blood, the microcirculation of blood, the hemoperfusion of tissue, vascular elasticity, bone health, blood coagulation ability, orthoplastocyte ability of aggregation, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, memory, alertness, psychology definition, weight management, triglyceride levels in blood, blood pressure, situation in the group of BMI and/or waistline, and/or described composition prevention diabetes, obesity, metabolic syndrome, arterial stiffness, chronic inflammation and/or low grade inflammation.
19. 1 kinds according to the composition described in any one in claim 1～12, described composition is used for the treatment of to be selected from and comprises vascular diseases, angiocardiopathy, atherosclerotic, artery sclerosis, obstruction of artery, blood vessel lacks flexibility, varication, arterial stiffness, transient ischemic attack, peripheral coldness, bone disease, bone demineralization, osteoporosis, DVT, apoplexy, diabetes, insulin resistance, high triglyceride blood level, metabolic syndrome, fat, the accumulation of body fat amount, high waistline, hypertension, chronic inflammation, low grade inflammation, mental disease, psychology goes down, situation in the group of dementia and/or Alzheimer's.
20. according to the application of the composition described in any one in claim 1～12, for supporting and/or maintaining or improve to be selected from, comprise vascular health, cardiovascular health, blood flow, blood circulation, the systemic circulation of blood, the microcirculation of blood, the hemoperfusion of tissue, vascular elasticity, bone health, blood coagulation ability, orthoplastocyte ability of aggregation, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, memory, alertness, psychology definition, weight management, triglyceride levels in blood, blood pressure, situation in the group of BMI and/or waistline, and/or prevention diabetes, obesity, metabolic syndrome, arterial stiffness, chronic inflammation and/or low grade inflammation.
21. according to the application of the composition described in any one in the biological effectiveness that strengthens vitamin K and/or farnoquinone and/or MK-7 in claim 1～12.
22. according to the application of the composition described in any one in the biologically active that increases vitamin K and/or farnoquinone and/or MK-7 in claim 1～12.
23. application in the level of the vitamin K in increasing mammalian and/or farnoquinone and/or MK-7 according to the composition described in any one in claim 1～12.
24. according to the MGP of the not carboxylated that in claim 1～12, the composition described in any one circulates in reducing mammalian and/or the not application in the level of the BGP of carboxylated.
25. according to the application in the level of the MGP of carboxylated that in claim 1～12, the composition described in any one circulates in increasing mammalian and/or the BGP of carboxylated.
26. according to the application described in any one in claim 23,24 or 25, wherein, in 12 weeks, preferably in 8 weeks, more preferably in 4 weeks, obtain MGP and/or the not reduction of the level of the BGP of carboxylated of the not carboxylated of circulation, and/or the increase of the level of the MGP of the carboxylated circulating in described mammalian and/or the BGP of carboxylated, and/or the increase of the level of the vitamin K in described mammalian.
27. 1 kinds are reduced in the MGP of the not carboxylated circulating in mammalian and/or the method for the level of the BGP of carboxylated not, by mammal being given according to the composition described in any one in claim 1～12.
28. 1 kinds of methods that are increased in the level of the MGP of the carboxylated circulating in mammalian and/or the BGP of carboxylated, by giving mammal according to the composition described in any one in claim 1～12.
29. 1 kinds of methods that increase the level of the vitamin K in mammalian, by giving mammal according to the composition described in any one in claim 1～12.
30. according to the method described in any one in claim 27,28 and/or 29, wherein, give according at least 4 weeks of composition described in any one in claim 1～12 preferred at least 8 weeks, and time period at least 12 weeks most preferably.
CN201280035691.8A 2011-05-20 2012-05-18 Composition comprising vitamin k2 Pending CN103687495A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2006823 2011-05-20
NL2006823 2011-05-20
PCT/NL2012/050350 WO2012161572A1 (en) 2011-05-20 2012-05-18 Composition comprising vitamin k2

Publications (1)

Publication Number Publication Date
CN103687495A true CN103687495A (en) 2014-03-26

Family

ID=46087632

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280035691.8A Pending CN103687495A (en) 2011-05-20 2012-05-18 Composition comprising vitamin k2

Country Status (4)

Country Link
EP (1) EP2709460A1 (en)
CN (1) CN103687495A (en)
RU (1) RU2606767C2 (en)
WO (1) WO2012161572A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428645A (en) * 2015-03-20 2017-12-01 诺西斯有限公司 The reduction menadione of solid form
CN108813262A (en) * 2018-07-02 2018-11-16 杭州相生相成科技有限公司 A kind of compound probiotic solid beverage containing DHA algal oil
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
CN110200086A (en) * 2019-07-03 2019-09-06 江南大学 A kind of fat or oil composition
CN111418653A (en) * 2020-03-12 2020-07-17 广东双骏生物科技有限公司 Fermented milk and preparation method and application thereof
WO2023178799A1 (en) * 2022-03-25 2023-09-28 南京盛德生物科技研究院有限公司 Pharmaceutical composition containing vitamin k2 for improving cardiovascular calcification, preparation method therefor and use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) * 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP2886129A1 (en) * 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
WO2016131993A2 (en) 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
IT201700085412A1 (en) * 2017-07-26 2019-01-26 Pharmanutra S P A Composition for use in the prevention and treatment of cardiovascular diseases
US20220175888A1 (en) * 2018-04-30 2022-06-09 National Institute Of Immunology Carboxylated osteocalcin for treatment of amyloidosis or diseases associated with abnormal protein folding
CN111345352A (en) * 2020-04-21 2020-06-30 临夏州燎原乳业有限公司 Contains vitamin K2Children's formula milk powder of yak milk mixed with sialic acid and preparation method
CN114451563A (en) * 2022-02-25 2022-05-10 内蒙古伊利实业集团股份有限公司 Composition, application thereof and food

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
WO2004019923A1 (en) * 2002-08-30 2004-03-11 Vitak Bv Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
CN101534807A (en) * 2006-07-14 2009-09-16 纳多制药股份公司 Pharmaceutical and nutraceutical products comprising vitamin k2
US20100278940A1 (en) * 2005-04-04 2010-11-04 Hl Distribution Company Calcium supplements
CN101969792A (en) * 2008-01-28 2011-02-09 菲仕兰产品有限责任公司 Methods and compositions for the treatment of bone conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
US20090136592A1 (en) * 2007-11-27 2009-05-28 Tanja Lautenschlager Vitamin preparation
RU2008128511A (en) * 2008-07-15 2010-01-20 Закрытое акционерное общество "Академия-Т" (RU) BALANCED NUTRITION FOR FUNCTIONAL BEVERAGES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
WO2004019923A1 (en) * 2002-08-30 2004-03-11 Vitak Bv Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
US20050261257A1 (en) * 2002-08-30 2005-11-24 Vitak Bv Compositions for treating or preventing cardiovascular disease
US20100278940A1 (en) * 2005-04-04 2010-11-04 Hl Distribution Company Calcium supplements
CN101534807A (en) * 2006-07-14 2009-09-16 纳多制药股份公司 Pharmaceutical and nutraceutical products comprising vitamin k2
CN101969792A (en) * 2008-01-28 2011-02-09 菲仕兰产品有限责任公司 Methods and compositions for the treatment of bone conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COCKAYNE S,ET AL.: "Vitamin K and the Prevention of Fractures:Systematic Review and Meta-analysis of Randomized Controlled Trials", 《ARCHIVES OF INTERNAL MEDICINE》, vol. 166, no. 12, 26 June 2006 (2006-06-26), pages 1256 - 1261, XP002678670, DOI: doi:10.1001/archinte.166.12.1256 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428645A (en) * 2015-03-20 2017-12-01 诺西斯有限公司 The reduction menadione of solid form
CN108813262A (en) * 2018-07-02 2018-11-16 杭州相生相成科技有限公司 A kind of compound probiotic solid beverage containing DHA algal oil
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
CN110200086A (en) * 2019-07-03 2019-09-06 江南大学 A kind of fat or oil composition
CN111418653A (en) * 2020-03-12 2020-07-17 广东双骏生物科技有限公司 Fermented milk and preparation method and application thereof
WO2023178799A1 (en) * 2022-03-25 2023-09-28 南京盛德生物科技研究院有限公司 Pharmaceutical composition containing vitamin k2 for improving cardiovascular calcification, preparation method therefor and use thereof

Also Published As

Publication number Publication date
RU2606767C2 (en) 2017-01-10
WO2012161572A1 (en) 2012-11-29
EP2709460A1 (en) 2014-03-26
RU2013156676A (en) 2015-06-27

Similar Documents

Publication Publication Date Title
CN103687495A (en) Composition comprising vitamin k2
US20020025983A1 (en) Vitamin K and essential fatty acids
NL2008294C2 (en) Food composition comprising vitamin k and saturated fat.
CN108720021A (en) DHA algal oil microscapsule powder and preparation method thereof
EP2247199A1 (en) Methods and compositions for the treatment of bone conditions
EP1286597B1 (en) Lipid composition and use thereof
US20090099261A1 (en) Omega-3 mixtures
JP2525624B2 (en) Baby milk powder containing polyunsaturated fatty acids
JP2017503790A (en) Composition comprising trivalent iron saccharate and high concentration of microencapsulated LC-PUFA and having reduced taste
JPH06169735A (en) Nutritious drink composition
JPS62224258A (en) Nourishing food
JP2001029010A (en) Nutrient composition
CN112352837A (en) Modified milk containing unsaturated fatty acid and preparation method thereof
EP1867242A1 (en) Production method of meat-based products with direct and indirect incorporation of plant and animal fatty substances as carriers of omega-3 and omega-6 fatty acids
WO2009127029A1 (en) Meat cuts added with omega-3 fatty acid and process to obtain meat cuts added with omega-3
JP2010516286A (en) Premix emulsion
Kiruthika Docosahexaenoic Acid (Dha)-The Magic of Master Brain
CN115104731B (en) Nutritional composition and food comprising said nutritional composition
Hendricks et al. Significance of milk fat in infant formulae
JP4997514B2 (en) Antihypertensive agent
JP2001258507A (en) Nutritional composition
ES2221576B1 (en) BLENDS OF OILS.
RU2440767C1 (en) Sterilised dairy product based on goat milk for pregnant and nursing women alimentation
WO2022163760A1 (en) Gel-like nutritional composition
GLANCE Essential Fatty Acids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326

RJ01 Rejection of invention patent application after publication